Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asymmetric Lipid Bilayer01:35

Asymmetric Lipid Bilayer

7.4K
Biological membranes show uneven distribution of different types of lipids in the inner and outer layers, resulting in transverse asymmetric membranes. The treatment of the erythrocyte membrane with the enzyme phospholipase confirmed the asymmetric nature of the lipid bilayer. The enzyme hydrolyzes lipids into fatty acids and hydrophilic groups. The phospholipase acts only on the outer layer of the membrane, while the inner layer remains intact. The phospholipase treatment resulted in 80%...
7.4K
Pore Transport and Ion-Pair Transport01:17

Pore Transport and Ion-Pair Transport

563
Pore transport and ion-pair formation are critical mechanisms for the absorption and distribution of drugs in the body.
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited  but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct...
563
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

2.5K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.5K
Biosynthesis of Lipids01:29

Biosynthesis of Lipids

63
Microbial membranes exhibit remarkable diversity in lipid composition, reflecting evolutionary adaptations to various environmental conditions. The three domains of life—Bacteria, Archaea, and Eukarya—synthesize membrane lipids through distinct biosynthetic pathways, leading to fundamental structural differences that impact membrane stability, function, and adaptability.Fatty Acid-Based Lipids in Bacteria and EukaryaBacteria and eukaryotes share a common fatty acid biosynthesis...
63

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim.

Antimicrobial agents and chemotherapy·2026
Same author

Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents.

The Journal of antimicrobial chemotherapy·2026
Same author

Real-world evaluation of isavuconazole in children with cancer.

The Journal of antimicrobial chemotherapy·2026
Same author

Intravenous lanadelumab for the treatment of moderately ill COVID-19 patients.

British journal of clinical pharmacology·2026
Same author

In vitro and clinical data demonstrate negligible risk of drug-drug interactions with opelconazole, a novel inhaled antifungal agent.

The Journal of antimicrobial chemotherapy·2025
Same author

A fluconazole population pharmacokinetics study to improve target attainment in critically ill patients.

Infection·2025

Related Experiment Video

Updated: Aug 20, 2025

Formulation and Characterization of Bioactive Agent Containing Nanodisks
07:58

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

1.2K

Liposomal amphotericin B-the past.

R J Brüggemann1,2, G M Jensen3, C Lass-Flörl4

  • 1Department of Pharmacy, and Radboudumc Institute of Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

The Journal of Antimicrobial Chemotherapy
|November 25, 2022
PubMed
Summary
This summary is machine-generated.

Liposomal amphotericin B, a key antifungal treatment, offers improved efficacy and safety for systemic fungal infections. Decades of research confirm its value in treating serious infections like aspergillosis and candidiasis.

More Related Videos

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

12.0K
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.0K

Related Experiment Videos

Last Updated: Aug 20, 2025

Formulation and Characterization of Bioactive Agent Containing Nanodisks
07:58

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

1.2K
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

12.0K
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.0K

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Amphotericin B, a polyene antifungal, has been vital for treating systemic fungal infections since the 1950s.
  • Liposomal amphotericin B formulation enhances drug delivery, improving therapeutic index by increasing plasma and tissue concentrations while reducing toxicity compared to conventional amphotericin B deoxycholate.

Purpose of the Study:

  • To review the history and characteristics of liposomal amphotericin B.
  • To examine key clinical studies detailing its pharmacokinetic, safety, and efficacy profile.
  • To present available microbiological data on its effectiveness against various pathogens.

Main Methods:

  • Literature review of historical data, preclinical studies, and clinical trials.
  • Analysis of pharmacokinetic and safety data from clinical use.
  • Compilation of microbiological efficacy data against fungal and protozoan pathogens.

Main Results:

  • Liposomal amphotericin B is established in international guidelines for treating infections like aspergillosis, cryptococcosis, candidiasis, and visceral leishmaniasis.
  • Over 30 years of use provide extensive data on its preclinical and clinical efficacy and toxicity.
  • The liposomal formulation demonstrates a favorable safety and efficacy profile for a broad spectrum of pathogens.

Conclusions:

  • Liposomal amphotericin B represents a significant advancement in managing systemic fungal infections.
  • Its established safety and efficacy profile supports its continued use and recommendation in clinical practice.
  • Ongoing research and data collection continue to refine understanding of its therapeutic applications.